FR2916976B1 - Utilisation de 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, pour la preparation de composition pharmaceutiques ou cosmetiques destinees au traitement ou a la prevention des desordres pigmentaires. - Google Patents

Utilisation de 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, pour la preparation de composition pharmaceutiques ou cosmetiques destinees au traitement ou a la prevention des desordres pigmentaires.

Info

Publication number
FR2916976B1
FR2916976B1 FR0755468A FR0755468A FR2916976B1 FR 2916976 B1 FR2916976 B1 FR 2916976B1 FR 0755468 A FR0755468 A FR 0755468A FR 0755468 A FR0755468 A FR 0755468A FR 2916976 B1 FR2916976 B1 FR 2916976B1
Authority
FR
France
Prior art keywords
thiones
tyrosinase
imidazole
inhibitors
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0755468A
Other languages
English (en)
Other versions
FR2916976A1 (fr
Inventor
Jean Guy Boiteau
Isabelle Pelisson
Itaru Suzuki
Branislav Musicki
Marielle Berthier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0755468A priority Critical patent/FR2916976B1/fr
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to KR1020097025382A priority patent/KR20100017632A/ko
Priority to CN200880018920A priority patent/CN101678000A/zh
Priority to RU2009148786/15A priority patent/RU2009148786A/ru
Priority to MX2009012711A priority patent/MX2009012711A/es
Priority to CA002688234A priority patent/CA2688234A1/fr
Priority to PCT/FR2008/050993 priority patent/WO2008152330A2/fr
Priority to AU2008263665A priority patent/AU2008263665A1/en
Priority to JP2010510855A priority patent/JP2010529095A/ja
Priority to EP08805933A priority patent/EP2164486A2/fr
Publication of FR2916976A1 publication Critical patent/FR2916976A1/fr
Application granted granted Critical
Publication of FR2916976B1 publication Critical patent/FR2916976B1/fr
Priority to US12/631,450 priority patent/US20100160401A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/42Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
FR0755468A 2007-06-05 2007-06-05 Utilisation de 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, pour la preparation de composition pharmaceutiques ou cosmetiques destinees au traitement ou a la prevention des desordres pigmentaires. Expired - Fee Related FR2916976B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0755468A FR2916976B1 (fr) 2007-06-05 2007-06-05 Utilisation de 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, pour la preparation de composition pharmaceutiques ou cosmetiques destinees au traitement ou a la prevention des desordres pigmentaires.
JP2010510855A JP2010529095A (ja) 2007-06-05 2008-06-04 色素障害の治療または予防における使用のための医薬または化粧品組成物の調製における、チロシナーゼ阻害剤としての4−フェニルイミダゾール−2−チオンの使用
RU2009148786/15A RU2009148786A (ru) 2007-06-05 2008-06-04 Применение 4-фенилимидазол-2-тионов в качестве ингибиторов тирозиназы для получения фармацевтических или косметических композиций, предназначенных для лечения или предупреждения нарушений пигментации
MX2009012711A MX2009012711A (es) 2007-06-05 2008-06-04 Uso de 4-fenil-imidazol-2-tionas como inhibidores de la tirosinasa, para la preparacion de composiciones farmaceuticas o cosmeticas destinadas al tratamiento o la prevencion de trastornos pigmentarios.
CA002688234A CA2688234A1 (fr) 2007-06-05 2008-06-04 Utilisation de 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, pour la preparation de compositions pharmaceutiques ou cosmetiques destinees au traitement ou a la prevention des desordres pigmentaires
PCT/FR2008/050993 WO2008152330A2 (fr) 2007-06-05 2008-06-04 Utilisation de 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, pour la préparation de compositions pharmaceutiques ou cosmétiques destinées au traitement ou à la prévention des désordres pigmentaires
KR1020097025382A KR20100017632A (ko) 2007-06-05 2008-06-04 색소성 장애의 치료 또는 예방에 이용하기 위한 약학 또는 화장 조성물의 제조에서의, 4-페닐이미다졸-2-티온 화합물의 타이로시나아제 억제제로서의 용도
CN200880018920A CN101678000A (zh) 2007-06-05 2008-06-04 用作酪氨酸酶抑制剂的4-苯基-咪唑-2-硫酮用于制备用来治疗或预防色素性疾病的药物或化妆品组合物的用途
EP08805933A EP2164486A2 (fr) 2007-06-05 2008-06-04 Utilisation de 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, pour la préparation de compositions pharmaceutiques ou cosmétiques destinées au traitement ou à la prévention des désordres pigmentaires
AU2008263665A AU2008263665A1 (en) 2007-06-05 2008-06-04 Use of 4-phenyl-imidazole-2-thiones as tyrosinase inhibitors for preparing pharmaceutical or cosmetic compositions for treating or preventing pigment disorders
US12/631,450 US20100160401A1 (en) 2007-06-05 2009-12-04 4-phenylimidazole-2-thione tyrosinase inhibitors and treatment or prevention of pigmentary disorders therewith

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0755468A FR2916976B1 (fr) 2007-06-05 2007-06-05 Utilisation de 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, pour la preparation de composition pharmaceutiques ou cosmetiques destinees au traitement ou a la prevention des desordres pigmentaires.

Publications (2)

Publication Number Publication Date
FR2916976A1 FR2916976A1 (fr) 2008-12-12
FR2916976B1 true FR2916976B1 (fr) 2009-09-04

Family

ID=38866280

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0755468A Expired - Fee Related FR2916976B1 (fr) 2007-06-05 2007-06-05 Utilisation de 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, pour la preparation de composition pharmaceutiques ou cosmetiques destinees au traitement ou a la prevention des desordres pigmentaires.

Country Status (11)

Country Link
US (1) US20100160401A1 (fr)
EP (1) EP2164486A2 (fr)
JP (1) JP2010529095A (fr)
KR (1) KR20100017632A (fr)
CN (1) CN101678000A (fr)
AU (1) AU2008263665A1 (fr)
CA (1) CA2688234A1 (fr)
FR (1) FR2916976B1 (fr)
MX (1) MX2009012711A (fr)
RU (1) RU2009148786A (fr)
WO (1) WO2008152330A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013083645A2 (fr) * 2011-12-07 2013-06-13 Unilever Plc Composition éclaircissante pour la peau

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798843A (en) * 1987-07-09 1989-01-17 Smithkline Beckman Corporation 2-mercaproimidazole dopamine-β-hydroxylase inhibitors
JPH05124923A (ja) * 1991-04-09 1993-05-21 Sansho Seiyaku Co Ltd メラニン生成抑制外用剤
JPH05132422A (ja) * 1991-04-09 1993-05-28 Sansho Seiyaku Co Ltd メラニン生成抑制外用剤
FR2917087B1 (fr) * 2007-06-05 2012-09-21 Galderma Res & Dev Nouveaux 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique.

Also Published As

Publication number Publication date
KR20100017632A (ko) 2010-02-16
WO2008152330A3 (fr) 2009-02-26
CA2688234A1 (fr) 2008-12-18
WO2008152330A2 (fr) 2008-12-18
JP2010529095A (ja) 2010-08-26
MX2009012711A (es) 2009-12-08
FR2916976A1 (fr) 2008-12-12
CN101678000A (zh) 2010-03-24
US20100160401A1 (en) 2010-06-24
RU2009148786A (ru) 2011-07-20
EP2164486A2 (fr) 2010-03-24
AU2008263665A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
EP2119477A4 (fr) Composition pour le traitement de la xérostomie ou de la sécheresse de la bouche
EP2224973A4 (fr) Conservateurs pour compositions cosmétiques, de toilette et pharmaceutiques
FR2921795B1 (fr) Utilisation d'une souche de bifidobacterium,pour la preparation d'une composition destinee a la prevention et/ou au traitement de manifestations de type allergique
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
WO2009141541A3 (fr) Utilisation d' inhibiteurs de kif13a et d ' ap-1 pour inhiber la melanogenese
CL2007003049A1 (es) Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
WO2011077043A3 (fr) Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
WO2009153496A3 (fr) Composes agonistes ppar, preparation et utilisations pour le traitement du diabete et/ou des dyslipidemies
WO2007024949A3 (fr) Agonistes d'alpha 2c adrenorecepteur
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
EP2257280A4 (fr) Nanoparticules ajustables modifiées pour la délivrance de substances thérapeutiques, produits diagnostiques et composés expérimentaux et compositions apparentées pour utilisation thérapeutique
WO2007141392A3 (fr) Compositions comprenant de l'acide bétulonique
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
WO2012046030A3 (fr) Inhibiteurs de phosphodiestérase
WO2009051718A3 (fr) Agents de modulation du récepteur du calcium
WO2010092088A3 (fr) Utilisation d'hydrophobine en tant qu'agent mouillant
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
WO2009024374A3 (fr) Formulations contenant de nouveaux composés dipolaires ioniques et leur utilisation
WO2008075173A3 (fr) Méthodes de traitement de troubles liés au podocyte
FR2887450B1 (fr) Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
WO2010046061A3 (fr) Préparations cosmétiques et/ou pharmaceutiques
WO2012075015A3 (fr) Compositions pharmaceutiques orales de métronidazole
EP2263668A4 (fr) Utilisation de polyphénols de thé dans la préparation de médicaments destinés à la prévention ou au traitement de tumeurs
FR2932385B1 (fr) Composition constituee d'extraits naturels microencapsules pour application buccale, cutanee ou muqueuse
FR2919187B1 (fr) Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140228